• Addiction sur ordonnance : la crise des antidouleurs, par Patrick Radden Keeke est disponible en version epub.


    Il y a des coïncidences qui ne trompent pas.

    Hier soir j’ai mis en place la vente de la version epub de « Addiction sur ordonnance : la crise des antidouleurs ».

    Et ce matin on apprend via le New York Times que Le Louvre a décidé de retirer le nom des Sackler, la famille à l’origine de cette crise, de l’aile du musée financée par leur « philanthropie ».

    C’est le bon moment pour mieux comprendre les tenants et aboutissants de cette affaire. Les opioïdes tuent plus de 50000 personnes aux États-Unis chaque année, plongent les familles dans l’angoisse et le déchirement. Cette crise à commencé parce que des médecins ont prescrit sans retenue OxyContin, un antidouleur opiacé soi-disant "non-addictif" produit par Purdue Pharma, l’entreprise des Sackler. Une entreprise plus spécialiste du marketing que de la pharmacie.

    Or cette famille apparait aux yeux des mondes de l’art comme composée de grands « philanthropes », en effectuant des donations aux musées et aux universités. Grâce à la photographe Nan Goldin, de multiples actions ont lieu dans ces institutions, dont celle au Louvre le 1 juillet qui ne doit pas être pour rien dans la décision du musée de retirer la mention des Sackler.

    L’enquête qui a rendu public le lien entre la pratique de la famille Sackler et la crise des opioïdes a été écrite par Patrick Radden Keefe et publiée dans le New Yorker... et c’est elle que nous avons traduit et publié dans « Addiction sur ordonnance »

    Cette enquête se lit comme un roman noir... très noir.

    Vous pouvez l’emporter cet été dans votre liseuse, ou commander la version imprimée :

    (et en principe dans la journée la version epub sera également disponible dans les diverses libraires numériques)

    Bonne lecture,

    Hervé Le Crosnier

    Addiction sur ordonnance : la crise des antidouleur
    Patrick Radden Keefe
    trad. de l’anglais par Claire Richard
    avec des compléments rédigés par Frédéric Autran, Cécile Brajeul et Hervé Le Crosnier
    Version imprimée - 16 € - ISBN 978-2-915825-90-9
    Version epub - 8 € - ISBN 978-2-915825-91-6
    commande, information et obtention d’un extrait spécimen :

    #Sackler #Opioides #C&F_éditions

  • Louvre Removes Sackler Family Name From Its Walls - The New York Times

    The Louvre in Paris has removed the name of the Sackler family from its walls, becoming the first major museum to erase its public association with the philanthropist family linked with the opioid crisis in the United States.

    The Louvre’s collection of Persian and Levantine artifacts is housed in a wing that has been known as the Sackler Wing of Oriental Antiquities since 1997.

    But on Wednesday, a plaque acknowledging the Sacklers’ donations had been removed from the gallery’s entrance, and references to “the Sackler Wing” on other signs in the museum had been covered with gray tape.

    Members of the Sackler family own Purdue Pharma, the maker of OxyContin, an enormously profitable and frequently abused painkiller that is the subject of numerous lawsuits in the United States.

    Les faux-culs !!!

    Nine other signs in the building that referenced the wing had been taped over. Ms. Aguirre said another large sign that acknowledged the Sackler donation had also been removed.References to “the Sackler Wing” have also been removed from the Louvre’s website.

    On Tuesday, Jean-Luc Martinez, the museum’s president, told RTL, a French radio station, that the Sackler name had been taken down because the Louvre’s policy on naming rights is that they last for 20 years.

    A spokeswoman for the Louvre did not respond to emails asking why, if naming rights only lasted 20 years, the name had not been painted over earlier.

    The Sackler family declined to comment through a spokesman from Edelman, the public relations firm that represents them in Britain.

    Ms. Goldin said she recognized that many museums could not follow the Louvre’s example without breaking their contracts, but she hoped they found a way. “I know that the museums, especially in America, have enormous trouble being funded and it’s so important museums stay open,” she said. “But museums are also about ethics and morality.”

    A spokeswoman for the Victoria and Albert Museum in London, which has a Sackler Courtyard, said in an emailed statement on Wednesday that the museum was “not considering the removal of any signage related to our past or present donors.”

    “We’re proud to have been supported by the Sacklers,” Tristram Hunt, the museum’s director, told the BBC on July 10.

    Tate did not intend to rename the Sackler escalator at Tate Modern, it said in an emailed statement on Wednesday.

    A spokeswoman for the Jewish Museum in Berlin said in a telephone interview on Wednesday that the Louvre’s move did not change an earlier statement about its Sackler staircase.

    “We will not be changing the name because we feel that renaming would be an inappropriate attempt to disguise what happened,” that statement, issued in March, said. “It would also contradict the fact that we acted in good faith.”

    #Opioides #Sackler #Louvre #Philanthropie

  • 76 billion opioid pills : Newly released federal data unmasks the epidemic


    America’s largest drug companies saturated the country with 76 billion oxycodone and hydrocodone pain pills from 2006 through 2012 as the nation’s deadliest drug epidemic spun out of control, according to previously undisclosed company data released as part of the largest civil action in U.S. history.

    The information comes from a database maintained by the Drug Enforcement Administration that tracks the path of every single pain pill sold in the United States — from manufacturers and distributors to pharmacies in every town and city. The data provides an unprecedented look at the surge of legal pain pills that fueled the prescription opioid epidemic, which has resulted in nearly 100,000 deaths from 2006 through 2012.

    Just six companies distributed 75 percent of the pills during this period: McKesson Corp., Walgreens, Cardinal Health, AmerisourceBergen, CVS and Walmart, according to an analysis of the database by The Washington Post. Three companies manufactured 88 percent of the opioids: SpecGx, a subsidiary of Mallinckrodt; ­Actavis Pharma; and Par Pharmaceutical, a subsidiary of Endo Pharmaceuticals.

    The database reveals what each company knew about the number of pills it was shipping and dispensing and precisely when they were aware of those volumes, year by year, town by town. In case after case, the companies allowed the drugs to reach the streets of communities large and small, despite persistent red flags that those pills were being sold in apparent violation of federal law and diverted to the black market, according to the lawsuits.

    In statements emailed to The Post on Tuesday, the drug distributors stressed that the ARCOS data would not exist unless they had accurately reported shipments and questioned why the government had not done more to address the crisis.

    “For decades, DEA has had exclusive access to this data, which can identify the total volumes of controlled substances being ordered, pharmacy-by-pharmacy, across the country,” McKesson spokeswoman Kristin Chasen said.

    A DEA spokeswoman declined to comment Tuesday “due to ongoing litigation.”

    The pain pill epidemic began nearly three decades ago, shortly after Purdue Pharma introduced what it marketed as a less addictive form of opioid it called OxyContin. Purdue paid doctors and nonprofit groups advocating for patients in pain to help market the drug as a safe and effective way to treat pain.

    But the new drug was highly addictive. As more and more people were hooked, more and more companies entered the market, manufacturing, distributing and dispensing massive quantities of pain pills.

    Purdue ending up paying a $634 million fine to the Food and Drug Administration for claiming OxyContin was less addictive than other pain medications.

    Annual opioid sales nationwide rose from $6.1 billion in 2006 to $8.5 billion in 2012, according to industry data gathered by IQVIA, a health care information and consulting company.

    Individual drug company revenues ranged in single years at the epidemic’s peak from $403 million for opioids sold by Endo to $3.1 billion in OxyContin sales by Purdue Pharma, according to a 2018 lawsuit against multiple defendants by San Juan County in New Mexico.

    During the past two decades, Florida became ground zero for pill mills — pain management clinics that served as fronts for corrupt doctors and drug dealers. They became so brazen that some clinics set up storefronts along I-75 and I-95, advertising their products on billboards by interstate exit ramps. So many people traveled to Florida to stock up on oxycodone and hydrocodone, they were sometimes referred to as “prescription tourists.”

    In 2007, the DEA brought a case against McKesson. The DEA accused the company of shipping millions of doses of hydrocodone to Internet pharmacies after the agency had briefed the company about its obligations under the law to report suspicious orders.

    “By failing to report suspicious orders for controlled substances that it received from rogue Internet pharmacies, the McKesson Corporation fueled the explosive prescription drug abuse problem we have in this country,” the DEA’s administrator said at the time.

    In 2008, McKesson agreed to pay a $13.25 million fine to settle the case and pledged to more closely monitor suspicious orders from its customers.

    That same year, the DEA brought a case against Cardinal Health, accusing the nation’s ­second-largest drug distributor of shipping millions of doses of painkillers to online and retail pharmacies without notifying the DEA of signs that the drugs were being diverted to the black market.

    “The depth and penetration of the opioid epidemic becomes readily apparent from the data,” said Peter J. Mougey, a lawyer for the plaintiffs from Pensacola, Fla. “This disclosure will serve as a wake up call to every community in the country. America should brace itself for the harsh reality of the scope of the opioid epidemic. Transparency will lead to accountability .”

    #Opioides #Oxycondone #Vente_opiacés #USA #Big_Pharma

  • Facebook Is Censoring Harm Reduction Posts That Could Save Opioid Users’ Lives

    As Facebook rolls out its campaign with the Partnership for Drug-Free Kids to “Stop Opioid Silence” and other initiatives to fight the overdose crisis, some stalwart advocates in the field are seeing unwelcome changes. In the past few months, accounts have been disabled, groups have disappeared, posts containing certain content—particularly related to fentanyl—have been removed, and one social media manager reports being banned for life from advertising on Facebook.

    In its efforts to stop opioid sales on the site, Facebook appears to be blocking people who warn users about poisonous batches of drugs or who supply materials used to test for fentanyls and other contaminants. Just as 1990s web security filters mistook breast cancer research centers for porn sites, today’s internet still seems to have trouble distinguishing between drug dealers and groups trying to reduce the death toll from the overdose crisis. VICE reviewed screenshots and emails to corroborate the claims made in this story.

    Facebook seems to be especially focused on fentanyl. Claire Zagorski, a wound care paramedic at the Austin Harm Reduction Coalition in Texas, said she informally surveyed other harm reduction groups about their experiences. About half a dozen reported problems with reduced distribution of posts or outright rejection—especially if they were trying to report a specific, local instance of fentanyl-tainted drugs. Two of the organizations affected were a harm reduction group called Shot in the Dark in Phoenix, Arizona, and Southside Harm Reduction Services in Minneapolis, Minnesota.

    “I think it’s important to remember that they’re not being like, ‘Hooray drugs!’" Zagorski said. "They’re saying, ‘Be warned that this contaminated supply could be lethal.’”

    Devin Reaves, executive director and co-founder of the Pennsylvania Harm Reduction Coalition, who hasn’t personally had posts blocked, said: “Facebook wants to address the opioid crisis, but when harm reductionists try to inform their communities about what’s dangerous, their posts are being blocked.”

    Why then is Facebook cracking down?

    When reached for comment, a Facebook spokesperson said the company is investigating these incidents. After VICE contacted Facebook, the company restored posts from Southside Harm Reduction and Shot in the Dark, as well as Louise Vincent’s ability to post her email address, which apparently triggered a spam filter unrelated to opioids.

    Facebook also told VICE that Marcom was blocked from posting ads due not to fentanyl test strips, but due to posts related to kratom, an herb used by some as a substitute for opioids. Facebook has decided that kratom is a “non-medical drug” and is removing posts and groups related to it—even though its use is considered to be a form of harm reduction.

    Marcom said he hadn’t posted any kratom-related ads since 2018 and added, “It’s extremely frustrating that they have chosen to ban a proven safe plant medicine, as Facebook used to be a space where tens of thousands went daily for help getting off of opiates and other pharmaceuticals.”

    #Facebook #Opioides #Liberté_expression #Régulation

  • Opioïdes : Nan Goldin vise le mécénat du Louvre - Libération

    La photographe a organisé lundi une action dans la cour du grand musée parisien, appelant sa direction à débaptiser une aile nommée en l’honneur d’une famille de mécènes détenant le laboratoire produisant l’Oxycontin, un puissant analgésique.

    Opioïdes : Nan Goldin vise le mécénat du Louvre

    Le Louvre n’imaginait sans doute pas voir un jour sa réputation ternie par la crise des opioïdes, ce scandale sanitaire majeur qui a déjà fait au moins 100 000 morts par overdose aux Etats-Unis. Le célèbre musée parisien doit pourtant faire face à une fronde inédite orchestrée par la photographe new-yorkaise Nan Goldin et le collectif PAIN (Pain Addiction Intervention Now), qui militent depuis deux ans pour alerter sur les dangers de l’Oxycontin. Ce puissant antidouleur, dérivé de l’opium, est commercialisé depuis 1996 par la société Purdue Pharma, elle-même détenue par la famille Sackler. Comme de nombreuses entreprises, le laboratoire américain est aussi un généreux mécène du monde de l’art, prêt à débourser de très grosses sommes pour voir son nom associé à des institutions culturelles de renom. Grâce à un don de 10 millions de francs au Louvre en 1996, la famille a ainsi obtenu que l’aile des antiquités orientales du Louvre soit nommée « aile Sackler », nom qu’elle porte toujours aujourd’hui. Douze salles consacrées à l’Iran ancien, au Levant et à l’Arabie ancienne, où trônent d’inestimables joyaux.

    Une association insupportable pour Nan Goldin, devenue la figure de proue de la lutte contre Sackler. Ancienne accro à l’Oxycontin dont elle est désormais sevrée, la photographe multiplie depuis 2017 les actions choc dans les musées financés par la famille américaine. Mais c’est la première fois qu’une action a lieu en France, face au musée le plus visité du monde.
    inRead invented by Teads
    « Sackler on meurt, le Louvre couvre »

    Les touristes présents lundi devant la pyramide du Louvre ont d’abord cru à une performance artistique. Entièrement vêtue de noir, sa médaille de l’ordre des arts et des lettres attachée à la ceinture, Nan Goldin s’est avancée dans l’eau au milieu du bassin, face au bâtiment de verre. Puis des militants ont déployé derrière elle une large banderole orange avec ces mots en lettres noires : « Louvre, take down their name » (« Louvre, retirez leur nom »). Une trentaine d’activistes se sont ensuite massés autour de la photographe aux cris de « Shame on Sackler » et « Sackler on meurt, le Louvre couvre ». « Sackler est responsable de la mort de 200 personnes par jour aux Etats-Unis, lance Nan Goldin aux quelques journalistes présents. Le Louvre ne peut pas être complice de ce scandale. »

    Préparée en trois semaines dans le plus grand secret, l’action a été menée en collaboration avec l’association Aides. « On ne parle que des Etats-Unis mais d’autres pays commencent à être touchés par la crise des opioïdes, explique Fred Bladou, chargé de mission au sein de l’asso. Ce désastre sanitaire doit aussi nous interpeller sur la politique préventive que nous menons. Il démontre l’absurdité qu’il y a à criminaliser les usagers de drogue illicite alors qu’une des plus grosses crises sanitaires de l’histoire concerne une drogue licite. » En France, une centaine de médecins ont alerté fin juin dans les colonnes du JDD sur « le risque d’une crise sanitaire » alors que « 12 millions de Français utilisent des médicaments opiacés, sans être alertés sur leur potentiel addictif et sur les risques d’overdose ».
    Guggenheim et Tate Modern

    Accusés de commercialiser son produit phare en toute connaissance de cause, les Sackler sont aujourd’hui visés par plus de 1 600 actions en justice dans 35 Etats américains. En mars, ils ont dû verser 270 millions de dollars dans le cadre d’un accord à l’amiable passé avec l’Etat de l’Oklahoma. Sous la pression de PAIN, la polémique s’est étendue au mécénat culturel international. Ces derniers mois, plusieurs grands musées comme le Guggenheim et le Metropolitan Museum of Art à New York, ou la Tate Modern à Londres, ont annoncé publiquement qu’ils refuseraient à l’avenir toute donation de la famille Sackler. Un autre musée londonien, la National Portrait Gallery, a décliné en mars un don d’un million de livres (1,15 million d’euros). « Nous n’avons plus reçu aucune donation ni aucune demande de Sackler depuis 1996 », se défend-on au Louvre. Mais ce refus des dons ne suffit plus, pour Nan Goldin et les militants de PAIN. « Il faut que le Louvre soit le premier à débaptiser une aile, exigent-ils dans leur communiqué. Nous n’acceptons plus qu’une institution culturelle publique financée par l’Etat et les contribuables porte au pinacle une entreprise meurtrière. »

    Techniquement, rien n’empêche le musée parisien de retirer le nom des Sackler, le choix de baptiser certaines salles n’étant pas irrévocable, selon la charte interne. Mais la problématique du mécénat et des donateurs embarrassants va bien au-delà de ce cas. Elle est d’autant plus sensible qu’en vingt ans, le budget du Louvre a plus que doublé, alors même que la subvention de l’Etat est restée stable (environ 100 millions d’euros par an). Pour financer la différence et satisfaire les dix millions de visiteurs annuels, le musée n’a d’autre choix que de se tourner vers les acteurs privés, qui représentent entre 20 et 25 millions d’euros par an. Pour vérifier l’origine de ces fonds, le Louvre s’appuie aussi bien sur son réseau diplomatique dans les ambassades étrangères que sur Tracfin, le service antiblanchiment de Bercy. A l’époque, la donation des Sackler n’avait soulevé aucun problème. Vingt-trois ans et plusieurs dizaines de milliers de morts plus tard, c’est une tout autre affaire.
    Emmanuel Fansten

    #Opioides #Sackler #Louvre

  • Opioïdes : Nan Goldin vise le mécénat du Louvre

    La photographe a organisé lundi une action dans la cour du grand musée parisien, appelant sa direction à débaptiser une aile nommée en l’honneur d’une famille de mécènes détenant le laboratoire produisant l’Oxycontin, un puissant analgésique.

    Préparée en trois semaines dans le plus grand secret, l’action a été menée en collaboration avec l’association Aides. « On ne parle que des Etats-Unis mais d’autres pays commencent à être touchés par la crise des #opioïdes , explique Fred Bladou, chargé de mission au sein de l’asso. Ce désastre sanitaire doit aussi nous interpeller sur la politique préventive que nous menons. Il démontre l’absurdité qu’il y a à criminaliser les usagers de drogue illicite alors qu’une des plus grosses crises sanitaires de l’histoire concerne une drogue licite. » En France, une centaine de médecins ont alerté fin juin dans les colonnes du JDD sur « le risque d’une crise sanitaire » alors que « 12 millions de Français utilisent des médicaments opiacés, sans être alertés sur leur potentiel addictif et sur les risques d’overdose ».

    • Je présume que oui car deux personnes sont venus me voire le soir du vernissage de l’expo à la Hall Saint Pierre ou je présente un dessin sur ce sujet ( réalisé grâce aux nombreuses infos partagé ici par @hlc merci @hlc ). Donc deux hommes sont venu me voire discrètement, un m’a dit s’être « sorti de cette merde » et l’autre est venu me dire qu’il était encore en plein dedans. Je les ai rencontré à Paris, mais c’est possible que ca ne soit pas des résidents français (à un vernissage c’est pas les catégories ouvrières qui sont les plus représentées). J’ai souvenir d’une émission radio sur la question des opioïdes en France, probablement france culture. Le médecin qui y intervenait trouvait que c’etait une classe de médicaments sous prescrit en France car selon lui nous n’avons pas une culture contre la souffrance, et les medecins ne préscrivent pas facilement des anti-douleurs en comparaison aux anglo-saxons qui sont très généreux là dessus. Je pense que c’est sur seenthis, je reviens mettre le lien si je trouve.
      Il y a aussi un article à ce sujet dans le livre de @hlc https://seenthis.net/messages/790327

      Edit : j’ai pas trouvé mais j’ai cet article qui devrais répondre à ta question

  • Cory Doctorow: Fake News Is an Oracle – Locus Online

    In the same way, science fiction responds to our societal ideomotor responses. First, the authors write the stories about the futures they fear and rel­ish. These futures are not drawn from a wide-open field; rather, they make use of the writer’s (and audience’s) existing vocabulary of futuristic ideas: robots, internets and AIs, spaceships and surveil­lance devices. Writers can only get away with so much exposition in their fiction (though I’ve been known to push the limits) and so the imaginative leaps of a work of fiction are constrained by the base knowledge the writer feels safe in assuming their readers share.

    So the writers write the stories. Then the editors choose some of those stories to publish (or the writers publish them themselves). Then readers choose some of those stories to elevate to the discourse, making them popular and integrating them into our vocabulary about possible futures, good and bad. The process of elevation is complicated and has a lot of randomness in it (lucky breaks, skilled agents, PR wins, a prominent reviewer’s favor), but the single incontrovertible fact about a SF work’s popularity is that it has captured the public’s imagination. The warning in the tale is a warning that resonates with our current anxieties; the tale’s inspiration thrums with our own aspirations for the future.

    Reading a writer’s fiction tells you a lot about that writer’s fears and aspira­tions. Looking at the awards ballots and bestseller lists tells you even more about our societal fears and aspirations for the future. The system of writers and readers and editors and critics and booksellers and reviewers act as a kind of oracle, a societal planchette that our hands rest lightly upon, whose movements reveal secrets we didn’t even know we were keeping.

    Which brings me to “fake news.”

    “Fake news” is a nearly useless term, encompassing hoaxes, conspiracy theories, unfalsifiable statements, true facts spoken by people who are seek­ing to deceive audiences about the identity of the speaker, and as a catch-all meaning, “I read a thing on the internet that I disagree with.”

    But for all that, “fake news” is useful in one regard: the spread of a given hoax, or unfalsifiable statement, or truth delivered under color of falsehood, or conspiracy, or objectionable idea undeniably tells you that the idea has caught the public imagination. The fake news that doesn’t catch on may have simply been mishandled, but the fake news that does catch on has some plausibility that tells you an awful lot about the world we live in and how our fellow humans perceive that world.

    The anti-vaxers have a point. Not about the safety of vaccines. I believe they are 100% wrong about vaccines and that everyone who can should get a full schedule of vaccines for themselves and their children.

    But anti-vaxers have a point about the process.

    About 20 years ago, Purdue Pharma introduced a new blockbuster pain­killer to replace its existing flagship product, MS Contin, whose patent had expired. The new drug, Oxycontin, was said to be safe and long-lasting, with effects that would last an incredible 12 hours, without provoking the fast adaptation response characteristic of other opioids, which drives users to take higher and higher doses. What’s more, the company claimed that the addictive potential of opioids was vastly overstated, citing a one-paragraph letter to the New England Journal of Medicine penned by Boston University Medical Center’s Dr. Hershel Jick, who claimed that an internal, un-reviewed study showed that opioids could be safely given at higher doses, for longer times, than had been previously thought.

    Purdue Pharma weaponized the “Jick Letter,” making it one of the most-cited references in medical research history, the five most consequential sentences in the history of NEJM. Through a cluster of deceptive tactics – only coming to light now through a string of state lawsuits – Purdue cre­ated the opioid epidemic, which has killed more than 200,000 Americans and counting, more than died in the Vietnam War. Purdue made $31 billion. The Sackler family, owners of Purdue, are now richer than the Rockefellers.

    The regulators had every reason to know something terrible was going on, from the small town pharmacies ordering millions of pills to the dead piling up on the streets of American cities and towns. The only way they could miss the opioid crisis and its roots in junk science was if they were actively seeking not to learn about it – and no surprise, given how many top regulators come from industry, and have worked at an opioid giant (and more: they are often married to pharma execs, they’re godparents to other pharma execs’ kids, they’re executors of pharma execs’ estates – all the normal, tight social bonds from the top players in concentrated industries).

    Ten years ago, if you came home from the doctor’s with a prescription for oxy, and advice that they were not to be feared for their addictive potential, and an admonition that pain was “the fourth vital sign,” and its under-treatment was a great societal cruelty, you might have met someone who said that this was all bullshit, that you were being set up to be murdered by a family of ruthless billionaires whose watchdog had switched sides.

    You might have called that person an “opioid denier.”

    #Fake_news #Cory_Doctorow #Science_fiction #Vaccins #Opioides

  • Inside the Elementary School Where Drug Addiction Sets the Curriculum - The New York Times

    Encore des descriptions terribles et lacrymales. Quand on sait que cette crise a été causée de prime abord par la cupidité et le cynisme des groupes pharmaceutiques...

    MINFORD, Ohio — Inside an elementary school classroom decorated with colorful floor mats, art supplies and building blocks, a little boy named Riley talked quietly with a teacher about how he had watched his mother take “knockout pills” and had seen his father shoot up “a thousand times.”

    Riley, who is 9 years old, described how he had often been left alone to care for his baby brother while his parents were somewhere else getting high. Beginning when he was about 5, he would heat up meals of fries, chicken nuggets and spaghetti rings in the microwave for himself and his brother, he said. “That was all I knew how to make,” Riley said.

    Riley — who is in foster care and who officials asked not be fully identified because of his age — is among hundreds of students enrolled in the local school district who have witnessed drug use at home. Like many of his classmates at Minford Elementary School, Riley struggles with behavioral and psychological problems that make it difficult to focus, school officials said, let alone absorb lessons.

    “If you’re worried about your parents getting arrested last night, you can’t retain information,” said Kendra Rase Cram, a teacher at Minford Elementary who was hired this past academic year to teach students how to cope with trauma. Over the past nine months, she led several classes a day, and met every week in one-on-one sessions with up to 20 students who have experienced significant trauma.

    “We have all these kids who are in survival mode,” Ms. Cram said.

    Minford Elementary is not like typical schools. At this small campus in rural southern Ohio, there is a dedicated sensory room stocked with weighted blankets, chewable toys and exercise balls. Children who were born dependent on drugs, as well as others with special needs, can take time to jump on a trampoline or calm down in a play tunnel, sometimes several times each day. In class, students role-play in lessons on self-control, such as blowing bubbles and then waiting to pop them, and anger management, while also learning calming strategies like deep breathing techniques.

    But the pastoral landscape belies a devastated community. In this county, long considered ground zero in Ohio’s opioid epidemic, nearly 9.7 million pills were prescribed in 2010 — enough to give 123 to each resident, the highest rate in the state, according to official statistics. Over the years, as opioid prescriptions have fallen, many drug users have moved on to heroin and fentanyl .

    #Opioides #Addiction #Enfants #Ohio #Ecole

  • Narcan Makes Fentanyl Overdoses Feel Safer to Some - The Atlantic

    The drug, which can shut down breathing in less than a minute, became the leading cause of opioid deaths in the United States in 2016. More and more drug users are seeking it out, craving its powerful high.

    Some of those users say they feel a measure of security because many of their peers carry naloxone, which can quickly restore their breathing if they overdose.

    Data suggest that in San Francisco, drug users may be reversing as many overdoses as paramedics—or more. In both cases, the numbers have risen sharply in recent years.

    Read: America’s health-care system is making the opioid crisis worse

    In 2018, San Francisco paramedics administered naloxone to 1,647 people, up from 980 two years earlier, according to numbers from the city’s emergency-response system.

    That compares with 1,658 naloxone-induced overdose reversals last year by laypeople, most of them drug users, according to self-reported data from the DOPE Project, a Bay Area overdose-prevention program run by the publicly funded Harm Reduction Coalition. That’s nearly double the 2016 figure.

    “People who use drugs are the primary witnesses to overdose,” says Eliza Wheeler, the national overdose-response strategist for the coalition. “So it would make sense that when they are equipped with naloxone, they are much more likely to reverse an overdose.”

    The widespread availability of naloxone has radically changed the culture of opioid use on the streets, Hogan said. “In the past, if you OD’d, man, it was like you were really rolling the dice.” Now, he said, people take naloxone for granted.

    “I feel like as long as there is Narcan around, the opiates can’t kill you,” says Nick Orlick, 26, referring to one of the brand names for the overdose-reversal drug.

    #Opioides #Overdoses #Naxolone

  • ‘Become My Mom Again’: What It’s Like to Grow Up Amid the Opioid Crisis - The New York Times

    More than 20 years after the introduction of OxyContin — and nearly 400,000 opioid overdose deaths later — a generation is growing up amid the throes of a historic epidemic. Call them Generation O: the children whose families are trapped in a relentless grip of addiction, rehab and prison. Here in Scioto County, a mix of verdant farmland and old mill towns on the southern edge of Ohio where everyone appears to know someone who has struggled with dependency, 51 people died of an overdose in 2017. At one school, administrators said, four kindergartners lost parents to drugs, and a fifth to a drug-related homicide.

    Nearly two dozen young people across the county described chaotic home lives rife with neglect and abuse. They recounted begging their parents — who more often spent money on the next fix than on food — to stop using drugs. And they described finding relatives unconscious or frothing at the mouth after overdosing. The interviews were coordinated by social workers, educators and community activists, and for those younger than 18, church staff, their guardians or their parents gave them permission to speak, and were present in some cases.

    Schools in Scioto County, educators said, have seen a surge in the number of children born addicted to opioids or suffering from neglect, many with severe learning disabilities, some barely able to speak. Teachers told of tantrums, at times violent, and of chairs thrown in classrooms.

    In a nation where more than 130 people die every day from an opioid overdose — and in a region where the impact of addiction has taken a severe emotional toll on children — school is for many students a refuge; a place where they attend classes, but also have access to hot meals, hot showers and donated clean clothes. On Fridays, educators said, students can take home backpacks full of food so they won’t go hungry over the weekend.

    Harrowing stories of living amid addiction spill out during play therapy sessions at school or in halting conversations with a sympathetic basketball coach. One recent afternoon, Christian Robinson, a lanky 18-year-old who plans to join the Marines after he graduates from high school, said his mom went to rehab when he was 11, but she relapsed last year on meth and heroin. She now lives in another city several hours away.

    “Mom has said that even us kids are not a good enough reason to stay clean,” Christian said. One of his sisters was born addicted to crack, he said, and a brother was born addicted to Oxycodone.

    “I’ve seen what drugs can do to a family and it’s not worth it to me,” he said.

    Amid the tumult, many children said they faulted themselves for not saving their parents from addiction. Others said they were made to feel guilty.

    #Opioides #Vie_d_enfer #Enfants

  • Nation’s first opioid trial could set precedent for massive pharma payouts - POLITICO

    The Oklahoma trial, which will be broadcast online, is expected to last for much of the summer, putting a national spotlight on the opioid crisis, which is still killing 130 people in the United States every day. The testimony will focus on how much manufacturers of highly addictive painkillers are to blame for getting patients hooked on opioids through misleading medical claims and aggressive marketing practices.

    The trial involving Johnson & Johnson will be closely watched by the hundreds of parties participating in the larger multi-district litigation overseen by U.S. District Court Judge Dan Polster, who has been pushing for a massive settlement before the first of those cases go to trial in the fall.

    “It’s going to be one of the first times that there will be evidence presented in an open forum about how we got to where we are,” said Joe Rice, co-lead counsel in the federal litigation targeting drugmakers and distributors in Ohio. “That’s a big question that a lot of people in the health community want to know. … Why and how did we get here?”

    On Sunday, Oklahoma also announced an $85 million settlement with Teva. That left Johnson & Johnson subsidiary Janssen Pharmaceuticals as the sole remaining defendant, barring a last-minute settlement.

    Purdue and its owners, the Sackler family, settled with Oklahoma for $270 million in March, which some state lawmakers and public health experts condemned as too meager. The biggest chunk of that settlement, $200 million, will be used to establish a new addiction treatment center at the University of Oklahoma. Another $60 million will be paid to attorneys involved in the case, and just $12 million will filter down to cities and towns struggling to deal with the addiction epidemic.

    Oklahoma Attorney General Mike Hunter stressed that the settlement was the best option because of the threat that Purdue would declare bankruptcy and the state might end up with nothing. But that means Oklahoma’s attorneys will have to make the potentially trickier case that other, less notorious players in the opioid pipeline created a “public nuisance” in the state by pushing misleading medical claims.

    #Opioides #Oklahoma #Sackler

  • Comparison of Opioid Prescribing by Dentists in the United States and England | Clinical Pharmacy and Pharmacology | JAMA Network Open | JAMA Network

    Key Points español 中文 (chinese)

    Question How do opioid prescribing patterns differ between dentists in the United States and dentists in England?

    Findings In this cross-sectional study of opioid prescribing by dentists in 2016, the proportion of dental prescriptions that were opioids was 37 times greater in the United States than in England.

    Meaning In light of similar oral health and dentist use between the 2 countries, it is likely that opioid prescribing by US dentists is excessive and could be reduced.

    #Opioides #Dentistes

  • Opinion | When Your Money Is So Tainted Museums Don’t Want It - The New York Times

    “Gifts that are not in the public interest.” It is a pregnant, important phrase. Coming on the heels of similar decisions by the Tate Modern in London and the Solomon R. Guggenheim Museum in New York, the spurning of Oxy-cash seems to reflect a growing awareness that gifts to the arts and other good causes are not only a way for ultra-wealthy people to scrub their consciences and reputations. Philanthropy can also be central to purchasing the immunity needed to profiteer at the expense of the common welfare.

    Perhaps accepting tainted money in such cases isn’t just giving people a pass. Perhaps it is enabling misconduct against the public.

    This was the startling assertion made by New York State in its civil complaint, filed in March, against members of the Sackler family and others involved in the opioid crisis. It accused defendants of seeking to “profiteer from the plague they knew would be unleashed.” And the lawsuit explicitly linked Sackler do-gooding with Sackler harm-doing: “Ultimately, the Sacklers used their ill-gotten wealth to cover up their misconduct with a philanthropic campaign intending to whitewash their decades-long success in profiting at New Yorkers’ expense.”

    “No amount of charity in spending such fortunes can compensate in any way for the misconduct in acquiring them,” Theodore Roosevelt said after John D. Rockefeller proposed starting a foundation in 1909. It was not a lonely thought at the time.

    But in the decades since, not least because of the amount of philanthropic coin that has been spent (can it still be called bribing when millions are the recipients?), touching all corners of our cultural life, attitudes have changed. And, as I found in spending the last few years reporting on nonprofits and foundations, a deeply complicit silence took hold: It was understood that you don’t challenge people on how they make their money, how they pay their taxes (or don’t), what continuing deeds they may be engaged in — so long as they “give back.”

    #Opioides #Sackler #Musées #Philanthropie

  • The Met Will Turn Down Sackler Money Amid Fury Over the Opioid Crisis - The New York Times

    The Metropolitan Museum of Art said on Wednesday that it would stop accepting gifts from members of the Sackler family linked to the maker of OxyContin, severing ties between one of the world’s most prestigious museums and one of its most prolific philanthropic dynasties.

    The decision was months in the making, and followed steps by other museums, including the Tate Modern in London and the Solomon R. Guggenheim Museum in New York, to distance themselves from the family behind Purdue Pharma. On Wednesday, the American Museum of Natural History said that it, too, had ceased taking Sackler donations.

    The moves reflect the growing outrage over the role the Sacklers may have played in the opioid crisis, as well as an energized activist movement that is starting to force museums to reckon with where some of their money comes from.

    “The museum takes a position of gratitude and respect to those who support us, but on occasion, we feel it’s necessary to step away from gifts that are not in the public interest, or in our institution’s interest,” said Daniel H. Weiss, the president of the Met. “That is what we’re doing here.”

    “There really aren’t that many people who are giving to art and giving to museums, in fact it’s a very small club,” said Tom Eccles, the executive director of the Center for Curatorial Studies at Bard College. “So we have to be a little careful what we wish for here.”

    There is also the difficult question of where to draw a line. What sort of behavior is inexcusable?

    “We are not a partisan organization, we are not a political organization, so we don’t have a litmus test for whom we take gifts from based on policies or politics,” said Mr. Weiss of the Met. “If there are people who want to support us, for the most part we are delighted.”

    “We would only not accept gifts from people if it in some way challenges or is counter to the core mission of the institution, in exceptional cases,” he added. “The OxyContin crisis in this country is a legitimate and full-blown crisis.”

    Three brothers, Arthur, Mortimer and Raymond Sackler, bought a small company called Purdue Frederick in 1952 and transformed it into the pharmaceutical giant it is today. In 1996, Purdue Pharma put the opioid painkiller OxyContin on the market, fundamentally altering the company’s fortunes.

    The family’s role in the marketing of OxyContin, and in the opioid crisis, has come under increased scrutiny in recent years. Documents submitted this year as part of litigation by the attorney general of Massachusetts allege that members of the Sackler family directed the company’s efforts to mislead the public about the dangers of the highly addictive drug. The company has denied the allegations and said it “neither created nor caused the opioid epidemic.”

    Nan Goldin, a photographer who overcame an OxyContin addiction, has led demonstrations at institutions that receive Sackler money; in March 2018, she and her supporters dumped empty pill bottles in the Sackler Wing’s reflecting pool.

    “We commend the Met for making the ethical, moral decision to refuse future funding from the Sacklers,” a group started by Ms. Goldin, Prescription Addiction Intervention Now, or PAIN, said in a statement. “Fourteen months after staging our first protest there, we’re gratified to know that our voices have been heard.”

    The group also called for the removal of the Sackler name from buildings the family has bankrolled. Mr. Weiss said that the museum would not take the more drastic step of taking the family’s name off the wing, saying that it was not in a position to make permanent changes while litigation against the family was pending and information was still coming to light.

    The Met also said that its board had voted to codify how the museum accepts named gifts, formalizing a longstanding practice of circulating those proposals through a chain of departments. The decision on the Sacklers, Mr. Weiss said, was made by the Met leadership in consultation with the board.

    #Opioides #Sackler #Musées

  • « Les patients n’ont pas l’impression d’être dans la transgression » - Libération

    A Clermont-Ferrand, plusieurs structures, dont l’Observatoire français des médicaments antalgiques, étudient la dépendance aux drogues légales que sont les opioïdes.

    Les consultations concernant les opioïdes se sont multipliées depuis 2014, quand les opioïdes sont devenus un sujet de recherche pour l’Institut national de la santé et de la recherche médicale (Inserm). « Les patients n’ont pas l’impression d’être dans un comportement de transgression vis-à-vis du traitement. Ils cherchent à se soulager, ce qui est légitime, explique Nicolas Authier. Parfois, ils n’ont plus de douleur physique mais continuent de prendre des médicaments pour calmer celle liée au manque et rendre moins pénible une douleur psychique préexistante, tel qu’un stress post-traumatique, un décès ou une maltraitance familiale. »

    #Opioides #France #Addiction

  • Opioïdes : les patients paient l’addiction - Libération

    Début avril, dans la septième édition de son rapport « Drogues et addictions, données essentielles », l’Observatoire français des drogues et des toxicomanies (OFDT) pointait pour sa part le rôle majeur joué par les opioïdes dans la mortalité des quinze dernières années en France. Les chiffres sont parlants : en l’espace de dix ans, le nombre annuel d’intoxications a doublé, si bien que l’Hexagone enregistre aujourd’hui plus d’overdoses par médicaments opioïdes que par l’usage de drogues illégales. Chaque semaine, environ cinq personnes meurent d’une overdose d’antidouleur opioïde, des suites d’une dépression respiratoire.

    Nathalie Richard : « Nous avons remarqué la progression d’un signal avec une augmentation des intoxications aux antalgiques opioïdes. La particularité de ce signal est qu’il ne concerne plus uniquement la population des usagers de drogue. Il progresse dans la population en général. »

    #Opioides #Addiction #France

  • Les Etats-Unis minés par la crise sanitaire de l’Oxycontin - Libération

    Il devait tuer les douleurs les plus tenaces. Il a beaucoup tué tout court. Combien d’Américains sont morts d’une overdose d’Oxycontin depuis la mise sur le marché de ce puissant analgésique, en 1996 ? Entre 100 000 et 200 000, si l’on en croit les statistiques officielles, parcellaires mais révélatrices de l’ampleur du phénomène. Un fait ne souffre aucune contestation : l’Oxycontin, alors présenté comme un médicament révolutionnaire et sans danger, a déclenché puis nourri la crise des opiacés qui ravage le pays depuis près d’un quart de siècle. Un fléau en perpétuelle mutation et au bilan humain considérable.

    Opioïdes : les patients paient l’addiction

    En 2017 (dernière année disponible), plus de 70 000 personnes ont succombé à une surconsommation de drogue aux Etats-Unis, en hausse de près de 10 % sur un an, signe que le pic de l’épidémie n’est pas atteint. De l’abondance de chiffres publiés par le Centre pour le contrôle et la prévention des maladies (CDC), on retiendra que plus de deux tiers de ces overdoses impliquaient des opiacés. Dans cette vaste famille de molécules dérivées de l’opium, le CDC distingue quatre sous-catégories : héroïne, méthadone, opiacés naturels et semi-synthétiques (comme l’Oxycontin) et, enfin, opiacés synthétiques de nouvelle génération, comme le surpuissant fentanyl, devenu la principale source d’inquiétude.

    Comment la première puissance mondiale a-t-elle pu se laisser ronger par une épidémie qui n’épargne aucune région, aucun milieu social ? Cela tient, fondamentalement, aux failles d’un système de santé largement privatisé et trop peu régulé. Des failles dans lesquelles des laboratoires pharmaceutiques se sont engouffrés, amassant des fortunes sur le dos de millions d’Américains rendus toxicomanes avec la complicité de distributeurs, médecins et pharmaciens sans états d’âme. Conçus pour soulager des douleurs sévères associées au cancer ou à la chirurgie, l’Oxycontin et d’autres opiacés ont été prescrits abusivement et en quantité colossale pour des douleurs plus légères. Déclenchant un cycle infernal d’addictions.

    #Opioides #Sackler

  • La famille Sackler, maîtres des #opioïdes et amis des arts

    Le déclic s’est produit lors des journées de charité du diocèse de Boston, pendant le Carême de 2016. Catholique et bon orateur, il vante l’action du diocèse en faveur des victimes de la drogue. Et évoque son frère. Une fois son discours achevé, une dizaine de personnes viennent partager leur expérience. A chaque fois, le même scénario : une blessure banale mais nécessitant un antidouleur, et une ordonnance d’#OxyContin. S’amorce alors l’engrenage de l’addiction avec, souvent, un basculement vers l’héroïne. Il s’agit bien d’une épidémie, provoquée par #Purdue et les Sackler.

    Pourquoi ferrailler avec une œuvre d’art ? Parce que c’est là une des failles du clan. Si le nom de Purdue est peu connu, celui de la famille Sackler est, depuis un demi-siècle, synonyme de mécénat artistique. Au Metro­politan Museum (Met) et au Musée Guggenheim de New York, à la National Portrait Gallery de Londres ou au #Louvre, à Paris, avec l’« aile ­Sackler des antiquités orientales », leur patronyme est omniprésent.

    Cela paie. En mars, le #Guggenheim a fait savoir qu’il n’accepterait plus de dons de la famille, ­ tandis que Mortimer #Sackler, ancien membre actif du conseil d’administration (CA) de Purdue et cousin de Richard, a dû se retirer du CA. A Londres, la #Tate Gallery a fait de même, et la National Portrait Gallery a décliné une promesse de don de 1 million de livres (1,15 million d’euros).

    L’histoire débute avec les trois frères Sackler, fils d’immigrants juifs de Galice et de Pologne nés à Brooklyn. Tous trois médecins psychiatres, ils se lancent dans la pharmacie, en rachetant une petite entreprise de Greenwich Village, qui vend des produits comme la Betadine ou fait le marketing du Valium. Ils conquièrent des patients et, surtout, des médecins prescripteurs (en 1997, le patriarche, Arthur Sackler, a été distingué à titre posthume pour ses talents publicitaires).

    Mais The New Yorker note qu’il s’agissait aussi de contrer l’arrivée de médicaments génériques, l’OxyContin devant tomber dans le domaine public en 2013. Et que l’effet paradoxal de l’affaire a été d’amplifier le basculement des drogués vers l’héroïne. « C’est un terrible paradoxe de l’histoire de l’OxyContin : la formule originelle a créé une génération accro aux pilules. Et sa reformulation (…) a créé une génération accro à l’#héroïne. »

    L’#Oklahoma, particulièrement touché, est parvenu fin mars à une transaction de 270 millions de dollars. Purdue préfère payer pour éviter un procès public et la publication de documents internes potentiellement désastreux. Des rumeurs de faillite courent, et certains Etats pourraient être tentés de conclure des transactions rapides plutôt que de ne rien obtenir.

  • Des #épidémies et des hommes... (3/4) : Crise des #opioïdes : l’Amérique en #overdose

    La dépendance aux opioïdes est devenue l’une des premières causes de mortalité du pays avec 70 000 personnes décédées d’une overdose en 2017, plus de six fois le nombre de personnes tuées par armes à feu la même année. La crise des opioïdes étant un problème qui se propage à grande échelle, les autorités ont du mal à la contrôler. Le gouvernement fédéral a dû décréter l’état d’urgence sanitaire il y a deux ans.

    Comment une telle crise sanitaire a-t-elle pu s’installer dans le pays le plus riche du monde ? Qui sont les responsables ? Que nous apprend cette épidémie du système d’accès aux soins états-unien et de son marché du #médicament ? Que nous révèle-t-elle de la crise multiforme traversée par les États-Unis ? Quelles sont les solutions pour les milliers de personnes tombées dans l’#addiction aux opioïdes ?

  • 10 000 morts au #Canada en 3 ans : l’association des utilisateurs de #drogues en croisade contre les surdoses

    Pour la seule année 2016, il y a eu près de 3000 morts, avec une moyenne d’hospitalisation quotidienne de 16 personnes.

    #santé #opioïdes

  • The Purdue Case Is One in a Wave of Opioid Lawsuits. What Should Their Outcome Be ? | The New Yorker

    Two years ago, when I was reporting on the opioid epidemic in one West Virginia county, the exorbitant cost of it—both socially and financially—perpetually astonished me. Narcan, the overdose-reversal drug, yanks people back from the edge of death to live another day and maybe, in time, conquer their addiction. Watching paramedics administer it was like witnessing a miracle over and over again. But Narcan is expensive—it cost Berkeley County, where I was reporting, fifty dollars a dose at the time, and consumed two-thirds of its annual budget for all emergency medications. Since then, the price of naloxone, its generic name, has risen to nearly a hundred and fifty dollars per dose, not because the formula has improved or become costlier to make—the drug has been around since 1961, and off patent since 1985—but because pharmaceutical manufacturers know a profitable market when they see one. According to the National Institute on Drug Abuse, an average of a hundred and thirty people fatally overdose on prescription or illicit opioids every day in the United States. The Centers for Disease Control and Prevention report that four hundred thousand Americans, a war’s worth of dead, died between 1999 and 2017.

    In Berkeley County, though, as in so many places across the country, Narcan accounted for just one column on a staggering spreadsheet. Hospitals have had to care for babies born in withdrawal. Foster-care systems have been strained by an influx of children whose families had been turned upside down by addiction. In many communities, the rates of H.I.V. and hepatitis C have climbed, because, once OxyContin pills were reformulated to make them harder to abuse, in 2010, and changes in prescribing practices made them more difficult to obtain, people addicted to them began injecting heroin and fentanyl instead.

    Under the Master Settlement Agreement, the tobacco companies also committed to pay the states two hundred billion dollars over twenty-five years, and to keep paying them sums tied to cigarette sales in each state in perpetuity. But nothing in the M.S.A. specified how that money was to be spent, and, though one might expect that the bulk of it would be dedicated to the goals of the lawsuits—reducing smoking and promoting public health—that has not generally been the case. In many states, much of the money has gone not to anti-smoking efforts, or even to general spending on health, but instead to closing budget shortfalls, lowering taxes, and funding infrastructure. States treated the agreement like what it felt like: a no-strings-attached gift.

    Je ne suis pas vraiment convainc par la conclusion :

    The Oklahoma settlement with Purdue is a reasonable stab at insuring that the money won in opioid lawsuits doesn’t follow a similar route. Yet some public-health advocates I spoke with said that, in the future, they hope more settlement money will go directly to the treatment of addiction. There’s good evidence, for example, that medication-assisted treatment using buprenorphine, naltrexone, or methadone works well for many people trying to get off opioids, but most states don’t have enough of it.

    Diriger les amendes vers la lutte contre les opioides es tune bonne chose, parce qu’elle évite le pire (que l’amende serve à « baisser les impôts »)... mais cela ne peut pas être un projet dans le cadre des procès. Une fois la responsabilité établie, il faut démanteler ces entreprises et ramener les familles qui les possèdent à un niveau de vie normal, car les Sackler ont largement organisé la promotion d’OxyContin. Or les accords à l’amiable doivent être acceptés par les deux parties, et les construire comme une fin en soi, c’est déjà baisser les bras devant la puissance financière (et donc la qualité/quantité des avocats...). Surtout quand une partie de l’amende sera comme en Oklahoma payée « en nature » par des médicaments produits par Purdue Pharma !!!

    #Opioides #Sackler #Procès

  • Plusieurs musées refusent les dons de la famille Sackler, propriétaire d’un laboratoire d’opioïdes | Slate.fr

    Après le National Portrait Gallery et le Tate à Londres, le musée Guggenheim de New York a lui aussi annoncé qu’il ne recevrait plus de dons de la part de la famille Sackler, révèle ABC News


    #PURDUE #mundiPHARMA #OxyContin #opioïde

  • First opioid settlement to fund ambitious addiction research center | Science | AAAS

    On 26 March, the state of Oklahoma agreed to drop its suit alleging deceptive marketing practices by Purdue in exchange for a National Center for Addiction Studies and Treatment at OSU’s medical complex in Tulsa. Purdue and the Sackler family, which owns the Stamford, Connecticut–based company, will provide a $177 million endowment for the national center, along with $20 million over 5 years for naloxone and other drugs to treat opioid addiction. The state is continuing its suit against several other companies, with opening arguments set for 28 May.

    The windfall for the new entity, which aspires “to become the premier addiction research center in the nation,” rewards OSU’s ambition. In October 2017, it opened a modest Center for Wellness and Recovery within its medical school to train future addiction medicine physicians, study the underlying causes of addiction and pain, provide treatment to those suffering from opioid use disorder, and educate the public about the burgeoning epidemic, which claims 130 lives a day in the United States and in 2017 killed nearly 800 Oklahomans. The center now has a staff of eight and a $2.4 million budget.

    Pas sûr que l’université qui va recevoir l’argent soit la plus adaptée, mais cela la remet en concurrence avec l’autre université d’Oklahoma.

    #Opioides #Oklahoma #Recherche

  • Purdue’s Sackler family fights ’inflammatory’ Massachusetts opioid case | Reuters

    La nouvelle bataille juridique des Sackler : expliquer qu’ils étaient juste les crétins utiles de Purdue Pharma votant les budgets.

    BOSTON, April 2 (Reuters) - Members of the Sackler family behind OxyContin maker Purdue Pharma LP have asked a judge to toss a lawsuit by Massachusetts’ attorney general claiming they helped fuel the U.S. opioid epidemic, arguing it contains “misleading and inflammatory allegations.”

    The wealthy family in a motion on Monday argued that Massachusetts Attorney General Maura Healey, who brought the suit, had mischaracterized internal records to create the “false impression” they personally directed privately-held Purdue’s marketing of painkillers.

    Her lawsuit, filed in June in Suffolk County Superior Court and revised earlier this year to include new allegations, was the first by a state to try to hold Sackler family members personally responsible for contributing to the opioid epidemic.

    The case is among roughly 2,000 lawsuits filed by state and local governments seeking to hold Purdue and other pharmaceutical companies responsible for the U.S. opioid crisis.

    Opioids were involved in a record 47,600 overdose deaths in 2017 in the United States, according to the U.S. Centers for Disease Control and Prevention.

    Healey’s complaint cites records to argue that family members, including Purdue’s former President Richard Sackler, personally directed deceptive opioid marketing while making $4.2 billion from Purdue from 2008 to 2016.

    They did so even after Purdue and three executives in 2007 pleaded guilty to federal charges related to the misbranding of OxyContin and agreed to pay a total of $634.5 million in penalties, the lawsuit said.


    But in their motion, the Sacklers said nothing in the complaint supports allegations they personally took part in efforts to mislead doctors and the public about the benefits and addictive risks of opioids.

    They said their role was limited to that of typical corporate board members who participated in “routine” votes to ratify the management’s staffing and budget proposals.

    “Not a single document shows an individual director engaging in any unlawful conduct regarding the sale of prescription opioids or ordering anyone else to do so,” the Sacklers’ lawyers wrote.

    Healey’s office had no comment.

    At least 35 states have cases pending against Purdue. A handful have also named Sackler family members as defendants, including Richard Sackler, Theresa Sackler and Mortimer D.A. Sackler.

    Last week, Purdue reached its first settlement in the recent wave of lawsuits, agreeing with the Sacklers to a $270 million deal with Oklahoma’s attorney general. The Sacklers were not named as defendants in Oklahoma’s lawsuit.

    Purdue had been exploring filing for bankruptcy before the accord’s announcement, Reuters reported in early March. (Reporting by Nate Raymond in Boston Editing by Noeleen Walder and Tom Brown)

    #Opioides #Sackler #Cynisme